Pieris Pharmaceuticals (NASDAQ:PIRS) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)’s share price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $16.95 and traded as low as $16.35. Pieris Pharmaceuticals shares last traded at $16.42, with a volume of 23,533 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 16th.

Pieris Pharmaceuticals Trading Down 2.2 %

The business’s fifty day simple moving average is $16.95 and its 200 day simple moving average is $13.26. The stock has a market cap of $21.68 million, a price-to-earnings ratio of -0.88 and a beta of 0.67.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($2.76) EPS for the quarter. Pieris Pharmaceuticals had a negative return on equity of 101.29% and a negative net margin of 39.71%.

Insiders Place Their Bets

In other Pieris Pharmaceuticals news, major shareholder Adar1 Capital Management, Llc bought 3,000 shares of the stock in a transaction on Monday, August 12th. The stock was purchased at an average price of $15.88 per share, with a total value of $47,640.00. Following the acquisition, the insider now owns 129,574 shares of the company’s stock, valued at approximately $2,057,635.12. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 8.89% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.